A New Analysis Makes Clear How Expensive It Will Be for Plans to Add Obesity Meds to Medicare

Plus, the crossover event of the year: TrumpRx is driving traffic to Mark Cuban Cost Plus Drugs

Looking Past the Tariff Headlines to Focus on Where the Impact Is ... and Is Not

And the White House budget proposal includes a huge boost in funding to oversee 340B

Lilly Wins FDA Approval for Its Foundayo Obesity Pill, Which Will Cost Between $149 and $349

Plus the drug industry gets a big appeals court win in the ongoing battle to set rules around 340B contract pharmacies

Drugmakers Aren’t Buying What the White House Is Selling on MFN

And a price war of sorts is emerging as Arrowhead and Ionis prepare to enter a large CV disease market

On a Busy Day for Pricing and Policy News, Here Are the Top 10 Stories

Vanda’s New Schizophrenia Drug Offers the Company a Way Out of Medicaid Inflation Penalties

And a new paper makes clear how quickly Chinese biopharma has risen

Yesterday Brought Two New Drug Approvals ... and Two Pricing Announcements

That’s notable, because, before yesterday, prices had not been publicly disclosed for a single med approved in 2026

The Impact of MFN, Especially Overseas, Remains Cloudy

And a legal case that seeks to close the 340B “STD loophole” kicks off

Introducing the TrumpRx Tracker

Introducing the TrumpRx Tracker

Government Watchdog Alleges CVS Caremark Overcharged a Federal Employee Health Plan by More than $600 Million

And a theory about the drip-drip-drip approach to putting medicines on TrumpRx

Trump Administration Official Offers Perspective on TrumpRx: ‘The Goal Was Not Actually Some Massive Reach’

And that official, Chris Klomp, also said that the White House is working on getting drugmaker buy-in on MFN legislation

A Plea From Congress to Providers on 340B Transparency: ‘If I Can't See It, I Can't Help You’

And looking at how TrumpRx prices compare to prices in the U.K. (plus Mark Cuban’s take on the site)

The NYT Refutes TrumpRx’s ‘World’s Lowest Prices’ Claim, But the Analysis Misses Key Context

Report on Flovent Pricing Shows How a Law Designed to Lower List Prices Can Boomerang

And the administration is still trying to get Congress to act on MFN legislation, but there’s not much evidence that the effort is working

GSK and Amgen Add Select Meds to TrumpRx, Offering New Angles on the Pharm-to-Table Future

And new insights on past, present, and future Medicare price “negotiations”

The Number of Americans Skipping Scripts Jumped Between 2023 and 2025, KFF Poll Finds

And three more medicines -- Novartis’ Mayzent, Rydapt, and Tabrecta -- have been added to TrumpRx

A New JAMA Paper Finds Hospitals Aren’t Sharing the Savings from Cancer Biosimilars

Three 340B Narratives to Watch: State Medicaid vs. 340B Providers, the Impact of 340B on Smaller Clinics, and What’s Next in STD Loophole Litigation

UCB releases its list- and net-price disclosures for 2025, making it the third company to show net prices continue to fall

CMS Announces Details on Its Plan to Bring Obesity Meds Into Medicare

But the details suggest that the Trump administration may struggle to get the effort off the ground

GSK’s Price Transparency Data Is Out; Net Prices Are Falling

And Novo will book an extra $4 billion in revenue, citing confidence that its 340B contract pharmacy policies are safe from legal challenges

Are Medicines on TrumpRx Seeing a Boost in Prescriptions? The Data Suggests the Answer Is (Mostly) ‘No’

And the reality that MFN may mean poor access in Europe, not lower prices in the U.S., begins to sink in

Lilly Supercharges the ‘Pharm-to-Conference-Table’ Ecosystem, Partnering With 18 Companies to Bring Lower Zepbound Prices to Employers

And a new resource that makes plain the extent -- and variability -- of hospital markups on pharmaceuticals

Sanofi’s Transparency Report Highlights the Continued Growth of Rebates Paid to Payers

And CMS ‘explanations’ for Medicare drug pricing suggest drugmakers and CMS didn’t see eye-to-eye in half of all ‘negotiations’

Pharmacists Say the Rollout of ‘Negotiated’ Prices in Medicare Is Leading to a Cash-Flow Crunch

And CMS extends the deadline for its MFN-in-Medicaid program in an effort to get small- and mid-size companies on board